Literature DB >> 28977481

Serum sickness-like disease after switching to biosimilar infliximab.

Marc Scherlinger1,2,3, Thierry Schaeverbeke1,2,3, Marie-Elise Truchetet1,2,3.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28977481     DOI： 10.1093/rheumatology/kex268

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  4 in total

1.  Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.

Authors:  Hillel P Cohen; Andrew Blauvelt; Robert M Rifkin; Silvio Danese; Sameer B Gokhale; Gillian Woollett
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 2.  Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.

Authors:  Meghna Jani; William G Dixon; Hector Chinoy
Journal:  Rheumatology (Oxford)       Date:  2018-11-01       Impact factor: 7.580

3.  Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.

Authors:  Brian G Feagan; Gordon Lam; Christopher Ma; Gary R Lichtenstein
Journal:  Aliment Pharmacol Ther       Date:  2018-11-08       Impact factor: 8.171

Review 4.  The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.

Authors:  Shahin Shams; Joseph M Martinez; John R D Dawson; Juan Flores; Marina Gabriel; Gustavo Garcia; Amanda Guevara; Kaitlin Murray; Noah Pacifici; Maxemiliano V Vargas; Taylor Voelker; Johannes W Hell; Judith F Ashouri
Journal:  Front Pharmacol       Date:  2021-05-28       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.